Blockchain pilot program aims to reform US drug supply chain

13 June 2019
blockchain_network_big

Merck & Co (NYSE: MRK) is to participate in a US Food and Drug Administration (FDA) pilot program that uses blockchain technology to improve the way medicines are identified, tracked and traced within the USA.

The New Jersey-based drugmaker will take part in the program, together with IBM, KPMG, and Walmart, in support of 2013 legislation, the US Drug Supply Chain Security Act (DSCSA).

The program is intended to help drug supply chain stakeholders, including the FDA, in developing the required infrastructure to implement the law.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Today's issue

Company Spotlight





More Features in Pharmaceutical